Diabetes and Cardiovascular Events in Women with Polycystic Ovary Syndrome: a 20-year Retrospective Cohort Study
Overview
Authors
Affiliations
Objective: Women with polycystic ovary syndrome (PCOS) are potentially at increased risk of cardiovascular (CV) diseases due to well-established risk factors, including insulin resistance, obesity and type 2 diabetes mellitus (T2DM). However, data showing excess CV events in this population are still lacking. We investigated the incidence and prevalence of CV events in a cohort of women with PCOS.
Design: Retrospective cohort study (total follow-up >12,000 person-years).
Setting: Leicester, Leicestershire and Rutland (Total Female population of 434,859), UK.
Participants: Two thousand three hundred and one women with PCOS (mean age = 29.6 years) attending a speciality clinic in Leicestershire, UK.
Main Outcomes Measures: T2DM, myocardial infarction (MI), angina, heart failure (HF), stroke and CV-related death.
Results: Incidence of T2DM, MI, angina, HF, stroke and CV death was respectively 3.6, 0.8, 1.0, 0.3, 0.0 and 0.4 per 1000 person-years. At the end of follow-up, the prevalence of MI in the age groups 45-54, 55-64 and >65 years was 1.9%, 6.0% and 27.3% and of angina was 2.6%, 6.0% and 27.3%, respectively. Age-group-specific odds ratios for the prevalence of MI and angina compared to the local female population ranged between 2.6 (95% CI: 1.0-6.3) and 12.9 (CI: 3.4-48.6) with the highest ratio being for MI in the group >65 years old. Age, history of hypertension and smoking had significant correlations with CV outcomes in the PCOS patients.
Conclusion: We have shown a high incidence and age-group-specific prevalence of T2DM, MI and angina in the women with PCOS, with over a quarter having had MI or angina in those >65 years. These findings should be considered in the treatment strategies and long-term planning for women with PCOS.
Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome.
Deng H, Chen Y, Xing J, Zhang N, Xu L Front Immunol. 2025; 15:1470283.
PMID: 39749338 PMC: 11693511. DOI: 10.3389/fimmu.2024.1470283.
The Current and Emerging Role of Statins in the Treatment of PCOS: The Evidence to Date.
Kolnikaj T, Herman R, Janez A, Jensterle M Medicina (Kaunas). 2024; 60(2).
PMID: 38399531 PMC: 10890374. DOI: 10.3390/medicina60020244.
Sharma P, Halder A, Jain M, Tripathi M J Hum Reprod Sci. 2024; 16(4):307-316.
PMID: 38322634 PMC: 10841935. DOI: 10.4103/jhrs.jhrs_13_23.
Effect of Dietary Regimen on the Development of Polycystic Ovary Syndrome: A Narrative Review.
Alomran S, Estrella E Cureus. 2023; 15(10):e47569.
PMID: 37881324 PMC: 10595043. DOI: 10.7759/cureus.47569.
Zhang X, Huangfu Z, Wang S Endocrine. 2023; 82(3):695-706.
PMID: 37668928 DOI: 10.1007/s12020-023-03467-8.